The study whether Sacubitril/Valsartan increase ultrafiltration and preserve residual kidney function in patients who are under peritoneral dialysis treatment.

Effecacy of Sacubitril/Valsartan in increasing ultrafitlation and preservation of residual kedny function in patients with peritoneal dialysis.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031230413

Enrollment

Registered

2023-10-19

Start date

2022-11-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney failure during peritoneal dialysis therapy Chrnoic kidney failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who obtained wrriten consent of participation in this research from patients or proxies. 2) Patinets who have hypertension or heart failure. 3) Patinets who underwent PET examination (PET, Weekly CCr, Weekly Kt/V, Daily urine volume mesurement) at least once.

Exclusion criteria

Exclusion criteria: 1) Patients who take any angiotensin-converting-enzyme inhibitors within 36 hours of the start of the study. 2) Patients who have had side effects in the past with the drug or its ingredients (valsartan and/or neprilysin).

Design outcomes

Primary

Measure	Time frame
Extracellular fluid volume by impedance method, daily water removal volume, daily urine volume, and daily sodium excretion	—

Secondary

Measure	Time frame
Edema, body weight, blood pressure, cardiothoracic ratio, serum creatinine, serum electrolytes, blood gases, PET, weekly Kt/V, weekly CCr, hANP, blood beta-2 microglobulin, cardiac function by echocardiography, flow mediated dilation measurement	—

Contacts

Public ContactRei Akiyoshi

Department of Nephrology, Dokkyo Medical University Saitama Medical center

ray219a@dokkyomed.ac.jp+81-48-965-1111

Outcome results